Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

150.00SEK
13 Sep 2019
Change (% chg)

6.00kr (+4.17%)
Prev Close
144.00kr
Open
145.00kr
Day's High
154.20kr
Day's Low
144.80kr
Volume
27,237
Avg. Vol
19,033
52-wk High
188.80kr
52-wk Low
128.00kr

Summary

Name Age Since Current Position

Carl Borrebaeck

71 2007 Chairman of the Board

Mats Grahn

57 2013 Chief Executive Officer

Hans Liljenborg

61 2013 Chief Financial Officer

Lotta Blomgren

59 2016 Operations Director

Henrik Winther

53 2017 Senior Vice President Business Development

Rolf Ehrnstrom

66 2013 Chief Scientific Officer

Linda Mellby

40 2018 Vice President Research & Development

Laura Chirica

51 2015 Chief Commercial Officer

Julie Silber

2019 Director of Investor Relations

Mimmi Ekberg

60 2018 Director

Christofer Sjogren

53 2018 Director

Hans Johansson

65 2017 Independent Director

Ann-Christine Sundell

55 2017 Independent Director

Biographies

Name Description

Carl Borrebaeck

Prof. Carl Borrebaeck has served as Chairman of the Board at Immunovia AB (publ) since 2007. Professor Carl Borrebaeck is a serial entrepreneur, having co-founded Immunovia AB, Senzagen AB, BioInvent International AB (BINV: Stockholm) and Alligator BioScience AB. Prof. Borrebaeck is a 2009 recipient of the AkzoNobel Science Award and was awarded the 2012 Gold Medal from the Royal Academy of Engineering Sciences in recognition of his ground-breaking research regarding biomarkers. In addition, Prof. Borrebaeck is previously the Vice-President of Lund University, Sweden (responsible for its Innovation systems); and currently Director of CREATE Health, a Translational Cancer Center; and chairman of the Department of Immunotechnology. He is Member of IVA. He is Chairman of the Board of Senzagen AB and CB Ocean Capital AB, member of the Board of Alligator Bioscience AB, Clinical Laserthermia Systems AB and Scandion A/S. Carl Borrebaeck is also partner in Immunova Handelsbolag. Carl Borrebaeck has previously been Board member of LU Innovation System AB, BioInvent International AB, Atlas Therapeutics AB and Medicon Village AB. He has also been Deputy Board member of Ideon Center AB and Endo Medical AB, among others.

Mats Grahn

Mr. Mats Grahn has served as Chief Executive Officer at Immunovia AB (publ) since 2013. Mats brings more than 25 years experiences in senior leading positions within the life science and diagnostics industry. He contributes with an extensive experience in business and strategic development, marketing, product management, product development and market access. Mats has a track record of leading international commercial operational organizations, restructuring of marketing organizations, integration of acquired companies as well as managing new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Previous positions include CVP Marketing Dako A/S, VP Product Management GE Healthcare, VP Marketing Amersham Biosciences, VP Laboratory Separations Pharmacia Biotech and VP Prevas Bioinformatics. He is Chairman of the Board and CEO of Gusmo AB and Deputy Director of Utas Glassmakeri AB. Previously, he was Chairman of the Board of Alligator Bioscience AB, Atlas Therapeutics AB och Bmatrix AB. He also held leading positions at Spiber Technologies AB and Biocrine AB. Mats Grahn holds a Master of Science in Engineering Physics from Lund University, Sweden.

Hans Liljenborg

Mr. Hans Liljenborg has served as Chief Financial Officer at Immunovia AB (publ) since 2013. Hans Liljenborg has a degree as subject teacher in Business Administration and Mathematics from Lund University, Sweden. Hans has long experience as Financial Manager for growing, global medical technology companies and has been Finance Director at Physio Control Inc, Jolife AB and Finance Manager at Vivoline Medical AB, listed on Nasdaq First North in March 2015. He also operates an own accounting firm. Hans Liljenborg is board member of ADAYS AB and deputy board member in Entreprenorskompetens i Lund AB, IES Interactive Executive Search AB, Gantus Training AB. Hans is also holder of Prosperus and auditor in Personalkooperativet Byns Forskola Ekonomisk forening. Previously, he held senior positions at E-vard MinDoktor.se Sverige AB, Jolife AB, Quick-Cool AB and Vivoline Medical AB. He was also Auditor at Bostadsrattsforeningen Langgardsgatan 17 and Solbacka Trading.

Lotta Blomgren

Ms. Lotta Blomgren has served as Operations Director at Immunovia AB (publ) since 2016. Lotta has more than 30 years’ experience within the life science and diagnostics industry, whereof 15 years in leading positions. She contributes with extensive experience from leading manufacturing, quality control and logistics teams, as well as managing transfer of new products from development to commercial scale. Her track record includes strategic reorganizations of international manufacturing networks, managing people and project portfolios, as well as due diligence of potential acquirement of new companies and Contract Manufacturing (CMO). Previous positions include VP Technical Operations at Euro Diagnostica AB, Head of Supply Chain Bioglan AB, Director Product & Technology Support Ferring A/S, Head of Process Development Ferring AB, cross functional roles within Process Development and Project Management at Astra AB, Kabi Pharmacia AB and ACO AB. Lotta Blomgren holds a M.Sc. in Chemical Engineering from Lund University, Sweden.

Henrik Winther

Mr. Henrik Winther has served as Senior Vice President Business Development at Immunovia AB (publ) since 2017. Henrik has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products. From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies. From 2013-2017, he continued at Agilent in Santa Barbara, CA, as Vice President and General Manager – as well as head of the R&D function – of the Companion Diagnostics Division, and in addition to scaling up the division, increased revenues significantly through fee-for-service collaborations with pharma and CDx-product releases. Henrik holds a DVM and PhD in cell biology and histology from University of Copenhagen. He has earlier worked as an Associate Professor within cell biology, but during the last 17 years focused on cancer diagnostics. He is Board Member of Saga Diagnostics AB.

Rolf Ehrnstrom

Mr. Rolf Ehrnstrom has served as Chief Scientific Officer at Immunovia AB (publ) since 2013. Rolf has more than 30 years of scientific, technical and commercial experience from small, medium and large sized life science and diagnostics companies on the international arena. The last 20 years he served in senior executive management roles. Rolf contributes with experience in product-, technology- and strategic development in the life science and diagnostics industry. He has a track record of leading operational organizations (>200 staff), restructuring of R&D organizations, integration of acquired companies as well as managing rapid growth in new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. His responsibilities have ranged from all technical disciplines within R&D as well as IP, Regulatory, Medical & Clinical Affairs, Scientific Relations/Profiling and External Scientific Collaborations. In recent years a special focus have been in the fields of Personalized Medicine, companion diagnostics and technology innovation where Dako has played a leading role within its field. His important previous positions include: CSO Dako-Agilent, CVP R&D Dako A/S, VP R&D Gyros AB, Science Director Amersham Biosciences, Senior Scientific Advisor Amersham Pharmacia Biotech, Senior Program Manager MicroArrays Amersham-Pharmacia Biotech, Director R&D Molecular Biology Pharmacia Biotech. In the CV are also roles as board member in scientific organization committees and small start-ups. He is Owner of Reomics AB and Independent Partner at Ventac-Partners. He also serves as Board Member of Reomics AB and Fluimedix A/S Danmark, as well as Member of the Nomination Committee of Idogen AB. Previously, he was Board Member of Biomonitor A/S. Rolf Ehrnstrom holds a Master of Science in Biochemistry & Biotechnology engineering from Royal Institute of Technology, Stockholm, Sweden.

Linda Mellby

Ms. Linda Mellby has served as Vice President Research & Development at Immunovia AB (publ) since 2018. She has previously been Laboratory Director since 2013. Linda has more than 10 years experience of recombinant antibody microarray technology, the Immunovia platform, she has deep knowledge about platform features, technology development as well as clinical applications within oncoproteomics and autoimmunity. She has been one of the key researchers managing the development of the Immunovia antibody microarray platform for disease proteomics, conducting extensive work related to process optimizations, standardizations as well as clinical studies. Linda Mellby received her Ph.D. in Immunotechnology from Dept. of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, in 2010, and a Master of Science in Chemistry Engineering in 2004.

Laura Chirica

Ms. Laura Chirica has served as Chief Commercial Officer at Immunovia AB (publ) since 2015. With more than 14 years experiences in leading commercial positions within the life science and diagnostics industry, Laura contributes with an extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms. Much of her experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Her previous positions include VP Sales and Marketing Euro Diagnostica AB, Director Purification Technologies Europe Sartorius Stedim, Global Marketing Director Dako A/S, and Global Marketing Program Manager GE Healthcare. She is Board Member of SenzaGen AB. Laura Chirica holds a Ph.D. in Biochemistry from Umea University, Sweden, a Master of Science in Biochemistry from Umea universitet and a Bachelor of Science in Biotechnology.

Julie Silber

Ms. Julie Silber is Director of Investor Relations of the company. Julie has served as a trusted advisor to small and medium size public companies as both an Investor Relations Officer and CFO. She has been instrumental in executing all facets of the IR function and leveraging her deep institutional investor knowledge and business consulting expertise. She is currently Senior IR Advisor at Wildeco inStockholm.

Mimmi Ekberg

Ms. Mimmi Ekberg has been Director of Immunovia AB (publ) since May 3, 2018. She has almost 30 years of experience of from the Pharmaceutical industry and 25 years within the oncology disease area. She has held different National and Nordic positions with experience of launches of specialist products. Mimmi has strategic and operational experience within Sales & Marketing for different indications in the Oncology area. She has experience as Business Unit Manager from E. Merck, Amgen and currently serves as the Business Unit Manager Oncology Nordic at Celgene, with a special focus on pancreatic cancer. Mimmi is educated as an Operating room nurse with various additional educations as Medical Oncology from Lund University, Clinical trials in Oncology Karolinska University hospital, and Executive Master of Business Administration from Stockholm University. She was Founder and board member of Anhorigfonden.

Christofer Sjogren

Mr. Christofer Sjogren has been Director of Immunovia AB (publ) since May 3, 2018. He has 15 years of experience in the financial industry as equity analysts in companies like Carnegie, Danske Bank (publ) and Deutsche Bank (publ) based in Stockholm. Christofer Sjogren has also been an Investor Relations consultant at Citigate Stockholm (formerly part of Huntsworth plc), and has been Vice President of Trelleborg AB (publ) for seven years as Head of Trelleborg Investor Relations. He is Board member Trelleborg Group Treasury.

Hans Johansson

Mr. Hans Johansson has been Independent Director of Immunovia AB (publ) since 2017. Hans Johansson has excessive experience and a wide network from his previous positions such as VP, Head of Companion Diagnostics at ThermoFisher Inc Speciality Diagnostics Group (with a turnover of USD 3 billion). Hans Johansson was also a former VP of Global Marketing and Commercial Development within the same company but at the ImmunoDiagnostics division and earlier VP, Head of the Laboratory Business Unit at Pharmacia Biotechnology. Hans has also been an active entrepreneur as CEO/Board member in the life science sector. Altogether, he has 30 years of experience from global business development and commercialization of biotechnical and diagnostic innovations. He holds M.Sc. in Chemical Engineering. He serves as Chairman of Doloradix AB and Myrtila AB and Board member of Uppsala Innovation Centre AB, Single Technologies AB earlier also board member at AffiBody AB, Duvbo affarskonsult AB and Chairman of the BoD for AroCell AB and member of the nomination committee at IscoNova AB.

Ann-Christine Sundell

Ms. Ann-Christine Sundell has been Independent Director of Immunovia AB (publ) since 2017. She has 30 years of experience from the medical device industry, where she has held various global positions. For 10 years she served as president for Genetic Screening, one of five strategic business areas with over 1500 employees worldwide within PerkinElmer. Ann-Christine has strategic and operational experience from areas where Immunovia is active such as Sales & Marketing, R&D, production, quality and compliance. She holds M.Sc. in Biochemistry. She serves as Chairman of the Board of Serres Oy andOy Medix Biochemica Ab, as well as member of the Board of Oy Medix Ab, Minerva Foundation for Medical Research, Raisio Oyj, Ledil Oy, Ledil Group OY, Revenio Group Oyj, Ab Archipelagia Golf Oy, BluePrint Genetics Oy. She also serves at Raisio Oyj’s research foundation and is Partner at AConsult. Previously, she was Board Member of Vanadis Ab and Zymonostics ApS.